Roche to acquire 89bio, will get pegozafermin for MASH in deal
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
Bylvay (odevixibat), an oral medication used to treat cholestatic pruritus — severe itching that results from a buildup of bile acids used in digestion —…
The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage…
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
Nesfatin-1 (NF-1), a hormone-like molecule that may ease cellular stress, reduced injury to the placenta in a mouse model of intrahepatic cholestasis of pregnancy…
The U.S. Food and Drug Administration (FDA) will evaluate the use of Fibroscan, a noninvasive test, to replace liver biopsies in clinical trials for metabolic…
An annual fundraising run in the Washington area becomes a monthlong, virtual event this year to raise funds and awareness for the rare pediatric liver…
The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against bulevirtide in adults with chronic…
Members of the primary biliary cholangitis (PBC) community have come together in September as part of PBC Awareness Month to build support and share…
Mutations in the LSR gene, including one previously unreported, were the likely cause of progressive familial intrahepatic cholestasis (PFIC) in two young children in Turkey,…